Autoimmunity and pregnancy loss

Seminars in Reproductive Medicine

Volumn 18, Issue 4, 2000, Pages 379-392

  Fausett, M Bardett ^a   Branch, D Ware ^b  

^a USAF Medical Center Keesler   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid antibody syndrome; Autoantibodies; Autoimmune diseases; Fetal death; Pregnancy loss; Recurrent miscarriage; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; HEPARIN; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; THYROID ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FETUS WASTAGE; GESTATIONAL AGE; HUMAN; IMMUNOTHERAPY; PREGNANCY RATE; RECURRENT ABORTION; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ABORTION, SPONTANEOUS; ANTIBODIES, ANTINUCLEAR; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOIMMUNITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; THYROID GLAND;

EID: 0034442054     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13728     Document Type: Article

References (115)

1. Syndrome of the black swan
2. The anticardiolipin syndrome
3. American society for reproductive immunology report of the committee for establishing criteria for diagnosis of reproductive autoimmune syndrome
4. Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus
5. Pregnancy outcome in women with systemic lupus erythematosus
6. Lupus pregnancy: II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient
7. Pregnancy outcome and autoantibodies in connective tissue disease
8. Prospective study of pregnancy in systemic lupus erythematosus: Results of a multidisciplinary approach
9. Pregnancy in patients with systemic lupus erythematosus
10. Outcome of pregnancy in patients with systemic lupus erythematosus: A prospective study
11. Problems associated with the management of pregnancies in patients with systemic lupus erythematosus
12. Systemic lupus erythematosus. Management during pregnancy
13. Pregnancy outcome in Thai patients with systemic lupus erythematosus
14. Outcome of planned pregnancies in systemic lupus erythematosus: A prospective study on 62 pregnancies
15. Fetal outcome of lupus pregnancy: A retrospective case-control study of the Hopkins Lupus Cohort
16. Perinatal outcomes in women with systemic lupus erythematosus
17. A study of 100 high risk lupus pregnancies
18. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: A cross-sectional study
19. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus
20. A prospective study on pregnancy risk of antiphospholipid antibodies in association with systemic lupus erythematosus
21. Hazards of lupus pregnancy
22. Pregnancy and lupus: Prognostic indicators and response to treatment
23. Effect of pregnancy in patients with lupus nephropathy
24. Lupus nephropathy and pregnancy: A study of 26 pregnancies in patients with systemic lupus erythematosus and nephritis
25. Lupus nephropathy and pregnancy: Report of 104 cases in 36 patients
26. Systemic lupus erythematosus in pregnancy
27. Systemic lupus erythematosus in pregnancy
28. Pregnancy in lupus nephritis and related disorders
29. Pregnancy in women with kidney disease
30. Glomerular disease and pregnancy: A study of 123 pregnancies in patients with primary and secondary glomerular diseases
31. Pregnancy in patients with systemic lupus erythematosus
32. Systemic lupus erythematosus and pregnancy
33. Systemic lupus erythematosus in pregnancy
34. Pregnancy in systemic lupus erythematosus
35. Pregnancy and its outcome in systemic lupus erythematosus
36. Pregnancy in lupus
37. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
38. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: A prospective analysis of 500 consecutive patients
39. Special report: The Second International Anticardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group
40. Anticardiolipin antibodies: Clinical consequences of "low titers."
41. Immunologic disease and fetal death
42. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population
43. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations
44. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience
45. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment
46. A study of sixty pregnancies in patients with the antiphospholipid syndrome
47. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies
48. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody
49. Immumoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: A model for autoimmune fetal loss
50. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies
51. The effect of human anticardiolipin antibodies on murine pregnancy
52. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3)
53. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients
54. Should anticardiolipin tests be performed in otherwise healthy pregnant women?
55. The incidence of phospholipid antibodies in the obstetric population
56. Lack of an association between late fetal death and antiphospholipid antibody measurements in the second trimester
57. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss: A case-control study
58. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
59. Antiphospholipid antibodies and fetal death
60. Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension
61. Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus
62. Lupus pregnancy: A prospective study of placental changes
63. Histopathological findings in placentae from patients with intra- uterine fetal death and anti-phospholipid antibodies
64. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies
65. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
66. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
67. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies
68. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization
69. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions
70. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy
71. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
72. Recurrent adverse pregnancy outcome and antiphospholipid antibodies
73. Fetal loss treatment in patients with antiphospholipid antibodies
74. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions
75. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
76. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H)
77. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
78. Fetal survival after prednisone suppression of maternal lupus-anticoagulant
79. Conformationally altered beta 2-glycoprotein I is the antigen for anticardiolipin autoantibodies
80. Clinical significance of beta 2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: Correlation with conventional antiphospholipid antibody detection systems
81. Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome
82. Anti-beta 2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome
83. Human reproductive failure is not a clinical feature associated with beta(2) glycoprotein-I antibodies in anticardiolipin and lupus anticoagulant seronegative patients (the antiphospholipid/cofactor syndrome)
84. Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions
85. Reproductive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: Preconception versus postconception treatment
86. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions
87. Autoantibodies to phospholipids and nuclear antigens in non-pregnant and pregnant Colombian women with recurrent spontaneous abortions
88. Antiphospholipid antibodies and recurrent pregnancy loss: Correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin
89. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity
90. Characteristics of high-titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death
91. The prevalence of autoantibodies and lupus anticoagulant in healthy pregnant women
92. Autoantibodies and pregnancy history in a healthy population
93. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss
94. Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology
95. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses
96. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome
97. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
98. Autoimmunity, fetal losses, lupus anticoagulant: Beginning of systemic lupus erythematosus or new autoimmune entity with gynaeco-obstetrical expression?
99. Sub-clinical autoimmune disease and unexplained abortion
100. Subclinical autoimmunity in recurrent aborters
101. The prognostic value of antinuclear antibodies in women with recurrent pregnancy losses: A prospective controlled study
102. Are antinuclear antibodies predictive of recurrent miscarriage?
103. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies
104. Pregnancy in patients with mild thyroid abnormalities: Maternal and neonatal repercussions
105. Antithyroid antibodies underlying thyroid abnormalities and miscarriage or pregnancy induced hypertension
106. Antithyroid antibodies and the association with non-organ-specific antibodies in recurrent pregnancy loss
107. Antithyroid antibodies in recurrent pregnancy loss
108. Thyroid antibody titer and avidity in patients with recurrent miscarriage
109. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction
110. Thyroid autoantibodies are not associated with recurrent pregnancy loss
111. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion: A controlled, prospective study of forty-four women
112. Antiphosphotipid antibodies in early repeated abortions: A case-controlled study
113. Antiphospholipid antibodies and recurrent abortion
114. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant
115. Anti-phospholipid antibodies and pregnancy loss